Chronic Hepatitis C
Conditions
Keywords
Peginterferon alfa-2a, ribavirin
Brief summary
The Chinese patients with chronic hepatitis C have a different genetic background, which had been demonstrated to significantly influence their responses to pegylated interferon and ribavirin. In this study, Chinese patients with Hepatitis C Virus genotype 1, 2/3, 6 infection were treated with pegylated interferon and ribavirin. Their response was compared amongst different genotypes.
Interventions
DRUG48-weeks course
patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
DRUGRibavirin
patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
Sponsors
Third Affiliated Hospital, Sun Yat-Sen University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* HCV RNA is positive * Treatment naive * Come from China
Exclusion criteria
* Active substance abuse * Poorly controlled psychiatric disease * HBsAg positive * Anti-HIV positive * Suffering from other significant concurrent medical conditions including chronic liver diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sustained virological response (SVR) | 24 weeks after the end of treatment | Undetectable HCVRNA in serum(\<15IU/ml) 24 weeks after the end of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Change in health related quality as measured by short form 36 (SF-36) from baseline to 24 weeks after the end of treatment | 24 weeks after the end of treatment |
| Sick leave in patients treated for 24 or 48 weeks treatment | 48 weeks |
Countries
China
Outcome results
None listed